


CANCER RESEARCH INSTITUTE

# IMMUNOTHERAPY PATIENT SUMMIT

San Francisco • Chicago • New York • Houston • Tampa



Chicago

August 5





**Jill O'Donnell-Tormey, Ph.D.**  
Chief Executive Officer  
and Director of Scientific Affairs

On behalf of the Cancer Research Institute (CRI), I thank you for joining us at the 2017 Immunotherapy Patient Summit. CRI is proud to be the world's leading nonprofit organization dedicated exclusively to harnessing the immune system's power to cure all cancers.

This important work has led to a promising new class of cancer treatments called cancer immunotherapy. These treatments can mobilize, strengthen, and sustain the immune system's ability to find and destroy cancer cells, wherever they are in the body.

CRI awards grants and fellowships to support scientists at leading research universities and clinics throughout the world. Our funding decisions are guided by a Scientific Advisory Council composed of renowned immunologists and tumor immunologists, including Nobel Prize winners and members of the National Academy of Sciences. CRI also offers educational programming on cancer immunotherapy for patients, caregivers, and healthcare professionals.

Immunotherapy has reached a tipping point and the involvement of patients, caregivers, and advocates is critical to helping ensure cancer patients of all types have access to these important new treatments. I look forward to a day of learning, networking, and sharing with all of you.

# Schedule of Events

---

9:00am	Registration and networking
10:00am	Program commences <b>Welcome</b> Brian Brewer <b>Introduction to the Cancer Research Institute</b> Jill O'Donnell-Tormey, Ph.D.
10:15am	<b>Hear from the experts</b> Learn the basics of immunotherapy Thomas Gajewski, M.D., Ph.D. Latest research update panel Moderator Thomas Gajewski, M.D., Ph.D. Panelists Gavin Dunn, M.D., Ph.D. Kunle Odunsi, M.D., Ph.D. Cassian Yee, M.D.
11:30am	<b>Patient perspective</b> Hear from a melanoma survivor Janie Ferling
12:00pm	Lunch and Networking

---

---

1:00pm

**Demystifying clinical trials**

Learn about clinical trials and panel discussion

Moderator

[Brian Brewer](#)

Panelists

[Janie Ferling](#)

[Donna Fernandez](#)

[Carol Roth](#)

2:15pm

**Breakout sessions**

Your choice of moderated discussion with our experts or a general networking session

Brain Cancer

[Gavin Dunn, M.D., Ph.D.](#)

Gynecologic Cancers

[Kunle Odunsi, M.D., Ph.D.](#)

Melanoma

[Cassian Yee, M.D.](#)

General Immunotherapy  
& Networking

[Thomas Gajewski, M.D., Ph.D.](#)

---

3:15pm

Program closes

---

9:00am – 4:00pm

**Clinical trial navigator appointments**

Appointments will be available all day. If you didn't pre-register, check with the registration desk.

---

# Faculty

## **Brian Brewer**

Mr. Brewer is director of marketing and communications at the Cancer Research Institute. In this role he helps the organization shape and promote its mission, always with an eye on the patient who will ultimately benefit from immunotherapy. Prior to this role, he was the grants program administrator and has served in a variety of capacities at CRI for over 19 years. Brian holds a Master of Public Administration from NYU's Robert F. Wagner Graduate School of Public Service.

## **Gavin Dunn, M.D., Ph.D.**

Dr. Dunn is a faculty member in the Department of Neurological Surgery with an appointment in the Department of Pathology and Immunology at Washington University, where he is a member of the newly established interdisciplinary Center for Human Immunology and Immunotherapy Programs. He oversees a research program focused on the immunobiology of malignant glioma with the goal of translational and clinical trial efforts in the treatment of this disease. His laboratory is focused on understanding the molecular and cellular basis of the immune response to glioblastoma in preclinical and translational settings as well as clarifying the relationships between glioma genomics and

immunogenicity, an area termed “cancer immunogenomics.” These investigations are complemented by ongoing clinical trial efforts in this area.

## **Janie Ferling**

Ms. Ferling was diagnosed with stage 3 metastatic melanoma in 2013. At the time, Janie's son was in high school and she was busy running her own business. Following surgery and interferon treatments, new tumors began to grow. The only treatments available for Janie to try were traditional chemotherapy drugs that were described to her as very toxic and not effective. Janie refused to quit. She began looking for a clinical trial and enrolled in a study testing a new treatment that combined two immunotherapies—infusions of the checkpoint inhibitor pembrolizumab (Keytruda®), and injections of a deactivated herpes virus-based treatment called T-Vec (Imlygic®), both of which have since received FDA approval as single-agent therapies in melanoma. After six months of treatment her tumors began to disappear. Today those tumors are gone and she just had her last infusion earlier this year. She will still need follow-up to ensure no reoccurrences but today Janie is living her life making more memories with her son.

## **Donna Fernandez**

Ms. Fernandez was first diagnosed with stage 4 lung cancer in 2012, when she went to the doctor believing she had a thyroid problem. At the time, Donna was working full time and doing dog agility several nights a week and every weekend. While her tumors did respond well to chemotherapy, as soon as the treatment ended her tumors grew back. When faced with starting another chemotherapy regimen, Donna instead enrolled in an immunotherapy clinical trial of nivolumab (Opdivo®). Donna responded immediately, her first scan showed that the tumors were completely stable and have remained so. Donna continues training with her two dogs, Cotton and Barney, and feels immunotherapy allows her to live her life exactly how she wants.

## **Thomas Gajewski, M.D., Ph.D.**

Dr. Gajewski is a professor in the Department of Pathology, Department of Medicine, and Ben May Department for Cancer Research at the University of Chicago. Dr. Gajewski, who received the first American Cancer Society-Jules L. Plangere Jr. Family Foundation Professor in Cancer Immunotherapy Award, is known for his work on the activation and regulation of T cells in

the cancer context, and he remains committed to translating those laboratory efforts into clinical strategies that can improve anti-tumor immune responses and clinical efficacy in patients.

## **Jill O'Donnell-Tormey, Ph.D.**

Dr. O'Donnell-Tormey is chief executive officer and director of scientific affairs at the Cancer Research Institute. She joined the organization in 1987, and has been chief executive since 1993. Prior to joining CRI, she served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University. Dr. O'Donnell-Tormey serves on the boards of SFO-Science Foundation for Oncology, Zurich, Switzerland; The City University of New York (CUNY); Richmond University Medical Center; and the Staten Island Foundation.

## **Kunle Odunsi, M.D., Ph.D.**

Dr. Odunsi is the deputy director of the Roswell Park Cancer Institute, where he also serves as the chair of the Department of Gynecologic Oncology and the executive director of the Center for Immunotherapy. He oversees all scientific and clinical research-related

initiatives, and works to transfer scientific discoveries into clinical settings. Dr. Odunsi has made significant research contributions, which include the characterization of tumor antigens and then using them to develop immunotherapy strategies for ovarian cancer patients. He is a fellow of both the Royal College of Obstetricians and Gynaecologists and the American College of Obstetricians and Gynecologists.

### **Carol Roth**

Ms. Roth was diagnosed with stage 4 glioblastoma, an aggressive form of terminal brain cancer, in the fall of 2015. After receiving surgery, chemotherapy, and radiation in Charlotte, NC, Carol's tumor grew and they found a second tumor, also on her brain. Wanting her life back, Carol began researching clinical trials and found a Cancer Research Institute-funded immunotherapy clinical trial testing a combination of treatments—the anti-PD-L1 checkpoint inhibitor durvalumab and the anti-angiogenic drug bevacizumab (Avastin®) in Boston. Within 8 months, one of Carol's tumors completely disappeared and the other shrunk by 80%. Today, Carol considers her condition very stable and remains busy at work and enjoying time off with her family and friends.

### **Cassian Yee, M.D.**

Dr. Yee is the director of Solid Tumor Cell Therapy in the Center for Cancer Immunology Research and a professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Yee is a pioneer in adoptive cell transfer (ACT) immunotherapy, which involves taking anti-cancer T cells from patients and then enhancing their anti-tumor capabilities before putting them back into patients. In this area, he helped establish standards for the process, demonstrated that these T cells can confer durable anti-tumor memory, and showed how checkpoint immunotherapy can enhance ACT's effects.





This event is made possible with generous support  
from the following sponsors:



**Bristol-Myers Squibb**



**MERCK**



AstraZeneca 

**Genentech**

 **NOVARTIS**

**REGENERON**

The 2017 Immunotherapy Patient Summit series  
takes place in the following cities:

**SAN  
FRANCISCO**

JULY 8



**CHICAGO**

AUG 5



**NEW YORK**

SEPT 23



**HOUSTON**

OCT 21



**TAMPA**

DEC 9



**REGISTER FOR LIVE  
STREAMING**

SEPT 23



[CANCERRESEARCH.ORG/SUMMIT](http://CANCERRESEARCH.ORG/SUMMIT)

